Company / SG&A Expense
MANNKIND CORP SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$144.1M
FY2025
5-year range
$77.4M / $144.1M
FY2021-FY2025
Trend
+52.8%
vs FY2024
Sector context
#96 of 211
Health Care
What the data says
At $144M, MANNKIND CORP's sg&a expense ranks #116 of 211 in the Health Care sector. SG&A Expense has increased for 5 consecutive years, from $59M in FY2020 to $144M in FY2025.
Based on SEC 10-K filings.
$144M in FY2025 with a 5-year CAGR of +19.5%.
Increased from $94M to $144M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +16.4%
- 5-Year CAGR
- +19.5%
- 10-Year CAGR
- -
Sector benchmark
#116 of 211 in Health CareTop 55% of 211This company $144.1M Sector average $728.7M
▼
-80.2% below sector average
Key checks
Key Insights
- MANNKIND CORP's sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +19.5%, indicating consistent growth.
- In FY2025, sg&a expense increased 52.8% year-over-year.
- Ranks #96 out of 211 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -2.74 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $144.1M | +52.8% |
| FY2024 | $94.3M | +0.0% |
| FY2023 | $94.3M | +3.1% |
| FY2022 | $91.5M | +18.2% |
| FY2021 | $77.4M | +31.1% |
| FY2020 | $59.0M | -20.9% |
| FY2019 | $74.7M | -6.3% |
| FY2018 | $79.7M | +6.3% |
| FY2017 | $75.0M | +59.7% |
| FY2016 | $46.9M | +14.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026